Harvard Bioscience forms scientific advisory board with four members

Harvard Bioscience, Inc. (Nasdaq: HBIO) announced the formation of a Scientific Advisory Board (SAB) to guide the company's research, development, and product roadmaps, according to a press release.

The SAB will meet quarterly and consists of five members, including President and CEO John Duke and four external industry figures.

The four outside members appointed to the board are:

Dr. Ryan Conder, Director of Epithelial and Organoid Systems at STEMCELL Technologies and adjunct professor at Simon Fraser University.

Dr. Aaron Goldman, founder and Director of the Drug Resistance Group at Brigham and Women's Hospital, with appointments at Dana-Farber Cancer Institute, Harvard Medical School, and Mass General Brigham. He also serves as an Operating Partner at BroadOak Capital Partners and an EIR at Memorial Sloan Kettering Cancer Center.

Dr. Keith Olson, CEO of Ananda Devices, who previously held roles at FujiFilm Cellular Dynamics and Life Technologies.

Eric Richman, a venture capitalist and board member at LabConnect, SafeHeal, Polarity Bio, MicroHealth Digital, and Tempo Therapeutics.

"The formation of our Scientific Advisory Board marks an exciting chapter for Harvard Bioscience," Duke said. "It brings together distinguished industry leaders to influence our R&D and new product roadmaps."

You May Also Be Interested In

• Tenable adds former Microsoft and AWS executive to its board
• Halozyme expands argenx deal to cover two more drug targets
• Navitas Semiconductor closes acquisition of Claros to expand AI power